{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125927","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.207573+00:00","generated_at":"2026-05-30T00:57:52.791993+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing","bullets":["Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.","Cash $257.2M as of Sept 30, 2024, up from $236.2M at Dec 31, 2023, due to $80M Sanofi upfront.","Phase 1b PIONEER trial for pociredir (SCD) advancing; Cohorts 3 (12mg) and 4 (20mg) planned; data expected 2025.","Losmapimod development suspended after Phase 3 REACH failure; company refocuses on pociredir and aplastic anemias.","Cash runway into at least 2027; FY2025 cash burn guided at $55-65M; expects ~$240M cash at end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125927","json":"https://secwatch.observer/filing/0000950170-24-125927.json","markdown":"https://secwatch.observer/filing/0000950170-24-125927.md","text":"https://secwatch.observer/filing/0000950170-24-125927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024125927/0000950170-24-125927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024125927/fulc-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:57:52.791993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}